Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Commodore Capital disclosed a buy of 400,161 shares of Spyre Therapeutics (NASDAQ:SYRE), an estimated $10.46 million trade based on quarterly average pricing, per a February 17, 2026, SEC filing. What happened According to a February 17, 2026, SEC filing, Commodore Capital increased its position in Spyre Therapeutics by 400,161 shares during the fourth quarter. The estimated transaction value is $10.46 million, based on the mean unadjusted closing price for the period. The quarter-end value of the stake ...